The story · written by gpt-6.1-sol,
On 2 April 1891, a federal court in Louisiana ordered a preliminary injunction protecting the name Bromidia. The medicine contained cannabis extract, but the dispute concerned the commercial identity of the product and the risk of misleading purchasers.
A medicine with cannabis among its ingredients
Judge Pardee’s opinion describes a preparation containing chloral hydrate, potassium bromide, extract of cannabis indica and extract of hyoscyamus. According to the case presented at the preliminary hearing, the complainants and their predecessors had used the coined name Bromidia from about 1877 and registered the trademark in 1881.
These details provide contemporary evidence of cannabis within a branded medicinal mixture. The opinion does not establish the quantities of its ingredients, clinical effectiveness or safety. Its description of an alleged private formula is part of the commercial dispute before the court.
The competing label
Finlay & Brunswig manufactured a substantially similar preparation. Their label called it a compound elixir of chloral and potassium bromide, but displayed Bromidia more prominently. Their own manufacturing name appeared below in smaller lettering.
The defendants argued that the name indicated the bromide ingredient and told customers that the preparation was substantially equivalent. They also maintained that printing their own name prevented confusion about who manufactured it.
Why the court intervened
Pardee treated Bromidia as an arbitrary trade name identifying the complainants’ goods. He concluded that the defendants’ use appropriated that commercial identity and could deceive an unsuspecting purchaser. Naming the competing manufacturer elsewhere on the label did not resolve the problem.
The court ordered the requested injunction pending the litigation. This entry records that preliminary decision, rather than treating it as a final judgment on every issue in the case.
The limits of the restriction
The opinion is a useful example of law governing the medicinal cannabis trade through ordinary commercial rules. Its operative concern was infringement of a product name. It did not prohibit cannabis cultivation, possession or medicinal preparation generally, nor did it create a special cannabis licensing system.
The original reporter scan, pages 796–798, was read for this article. The decision appears as unscored context in the United States history, alongside earlier poison-sales legislation. Together these sources show distinct legal questions affecting cannabis products before 1900.[1]
Listed for context. No score change is recorded for United States here.
References
- Battle & Co. v. Finlay, 45 F. 796 (1891)United States Circuit Court for the Eastern District of Louisiana · In Federal Reporter, volume 45 · 1891 · pp. 796–798; preliminary injunction, 2 April 1891; Pardee J.archived
Checked. The date and the event were compared with a source that was read.